Son of sevenless homologue 1 (SOS1) protein is universally expressed in cells and plays an
important role in the RAS signaling pathway. Specifically, this protein interacts with RAS in …

KRAS mutations are one of the most frequent activating alterations in carcinoma. Recent
efforts have witnessed a revolutionary strategy for KRAS G12C inhibitors with exhibiting …

SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of
KRAS to cycle through its “on” and “off” states. Disrupting the SOS1: KRASG12C protein …

The impact of genetic ablation of SOS1 or SOS2 is evaluated in a murine model of
KRASG12D-driven lung adenocarcinoma (LUAD). SOS2 ablation shows some protection …

KRAS is the most commonly mutated oncogene. Targeted therapies have been developed
against mediators of key downstream signaling pathways, predominantly components of the …

Within the MAPK/RAS pathway, there exists a plethora of protein–protein interactions (PPIs).
For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes …

Introduction: Up to 30% of all human cancers are driven by the overactivation of RAS
signaling. Son of Sevenless 1 (SOS1) is a central node in RAS signaling pathways and …

Chiral amine synthesis remains a significant challenge in accelerating the design cycle of
drug discovery programs. A zirconium hydride, due to its high oxophilicity and lower …

The SOS family of Ras-GEFs encompasses two highly homologous and widely expressed
members, SOS1 and SOS2. Despite their similar structures and expression patterns, early …

Intrinsic and acquired resistance limit the window of effectiveness for oncogene-targeted
cancer therapies. Here, we describe an in situ resistance assay (ISRA) that reliably models …